The recent launch of ACHIEVE Africa — Advancing Capacity for Health Innovation, Equity, and Vaccine Ecosystems in Africa — marks an important African-led effort to accelerate the development of safe, effective vaccines and biologics across the continent.

Announced on the margins of the 39th African Union General Assembly in Addis Ababa, the initiative signals a decisive shift toward true vaccine and therapeutic sovereignty through strengthened research, GMP-compliant manufacturing, regulatory systems, and resilient supply chains.

“Africa has the scientific talent needed to develop and produce vaccines and biologics,” said Dr. Patrick Lukulay, Bio Usawa’s Chief Operating Officer. “ The opportunity now is to align investment, partnerships, and policy to fully unlock that potential.”

This momentum aligns strongly with the mission of Bio Usawa, which is focused on advancing locally driven biomanufacturing and innovation to improve access to lifesaving health solutions across the continent.

As global health financing tightens, companies like Bio Usawa demonstrate that leadership, innovation, and impact can come from within.